CHMP Backs Innovent Biologics’ Sintilimab – PD‑1 Immunotherapy Recommended for EU Approval in Advanced Non‑Squamous NSCLC

Fineline Cube
4 Min Read
Summarize with AI

Innovent Biologics (HKG: 1801) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of sintilimab (European trade name: Zybrivo) in combination with chemotherapy for the treatment of adult patients with advanced non‑squamous non‑small cell lung cancer (NSCLC). The recommendation positions Innovent’s fully human anti‑PD‑1 antibody to become an additional first‑line treatment option for eligible patients in Europe, backed by a demonstrated survival benefit in the pivotal ORIENT‑11 trial.

- Advertisement -

Regulatory Milestone

ItemDetail
AgencyCHMP / EMA (European Union)
Opinion TypePositive opinion recommending marketing authorization
ProductSintilimab (EU trade name: Zybrivo) + chemotherapy
IndicationAdult patients with advanced non‑squamous NSCLC, first line
ClassFully human IgG4 anti‑PD‑1 monoclonal antibody (immunotherapy)
Announcement Date16 November 2026
Next StepsEuropean Commission final decision on marketing authorization following the CHMP opinion

Drug Profile & Mechanism of Action

  • Molecule: Sintilimab (Zybrivo) – a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD‑1), restoring anti‑tumor immune response.
  • Combination Strategy: Paired with chemotherapy in the first‑line setting, the regimen is designed to convert chemotherapy‑induced antigen release into a durable immune‑mediated anti‑tumor effect.
  • China Approval Footprint: Approved for ten indications in China, spanning squamous NSCLC, EGFR‑ and ALK‑negative non‑squamous NSCLC, non‑squamous NSCLC after EGFR TKI progression, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, endometrial cancer, colon cancer, renal cell carcinoma, and classical Hodgkin lymphoma.

Clinical Evidence – ORIENT‑11 Study

EndpointSintilimab + ChemotherapyPlacebo + ChemotherapyRelative Benefit
Median Progression‑Free Survival (PFS)8.9 months5.0 months52% reduction in risk of disease progression or death
Median Overall Survival (OS)24.2 months16.8 months35% reduction in risk of death

The CHMP recommendation is based on results from the ORIENT‑11 study, which demonstrated that compared with placebo plus chemotherapy, sintilimab in combination with chemotherapy reduced the risk of disease progression or death by 52% (median PFS: 8.9 vs. 5.0 months) and reduced the risk of death by 35% (median OS: 24.2 vs. 16.8 months). These findings confirm the clinical benefit of sintilimab plus chemotherapy and its potential to provide an additional first‑line treatment option for eligible patients with advanced non‑squamous NSCLC in Europe.

Market Impact & Outlook

  • Globalization Milestone: The positive opinion advances sintilimab toward EU authorization as Zybrivo, a landmark for Innovent Biologics’ international expansion and for China‑developed PD‑1 immunotherapies entering the European market.
  • Survival‑Backed Differentiation: A 35% reduction in risk of death and a 7.4‑month median OS gain over chemotherapy alone in ORIENT‑11 provide a compelling efficacy package for formulary and reimbursement negotiations in Europe’s crowded first‑line NSCLC landscape.
  • Broad Indication Base: Ten approved indications in China – spanning lung, liver, gastric, esophageal, gynecologic, colorectal, renal, and hematologic malignancies – demonstrate the molecule’s platform breadth and support potential subsequent EU line extensions.
  • Competitive Positioning: First‑line advanced non‑squamous NSCLC remains one of the largest immunotherapy markets globally; Zybrivo’s entry would give European oncologists an additional anti‑PD‑1 combination choice alongside established standards of care.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review of sintilimab (Zybrivo), the anticipated European Commission decision following the CHMP opinion, commercialization plans in the EU, and pipeline expectations. Actual results may differ due to risks including final regulatory determinations, market adoption, reimbursement negotiations, clinical outcomes, and competitive dynamics.-Fineline Info & Tech

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *